Crizotinib (brand name: Xalkori, Sekuri; Incepta).
Original price was: £379.00.£249.00Current price is: £249.00.
Crizotinib is a multi-target protein kinase inhibitor developed by Pfizer in the United States. It has demonstrated significant clinical efficacy in patients with tumors characterized by abnormal ALK, ROS1, and MET kinase activity.
MedFind provides access to Crizotinib through verified overseas procurement channels, with guaranteed authenticity, in-stock availability, rapid shipping, full logistics tracking, and privacy-protected handling. Professional guidance is available upon inquiry, including information on indications, clinical efficacy, adverse effects, and medication usage instructions.
Description
Product introduction:
Crizotinib is a multi-target protein kinase inhibitor developed by Pfizer in the United States. It has demonstrated significant clinical efficacy in patients with tumors harboring abnormal ALK, ROS1, and MET kinase activity. Crizotinib (Chinese brand name: Xalkori/Saikueri) was approved for import by the China Food and Drug Administration (SFDA) in February 2013.
Brand introduction:
Incepta Pharmaceuticals is the second-largest pharmaceutical company in Bangladesh, founded in 1999. It currently operates a portfolio of 783 products, exports to 59 countries, and continues to expand globally. The company has obtained GMP certifications from countries including the United Kingdom, Germany, and Canada.
Indications:
Indicated for the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC) with ALK, ROS1, or MET-positive mutations.
Dosage and administration:
Take one capsule twice daily, once in the morning and once in the evening at consistent times.
Capsules should be swallowed whole; do not chew, crush, dissolve, or open them.
May be taken with or without food. Do not take with grapefruit juice.
Dose adjustments should be made under medical supervision based on individual safety and tolerability.
Reviews
There are no reviews yet.